Found 305 articles
Actinium Highlights Foundational Patents Covering the Composition of Apamistamab Antibody and Iomab-B Antibody Radiation Conjugate for Targeted Conditioning Until 2037 and Recent EU Patent Activity
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today highlighted its intellectual property portfolio for apamistamab, a CD45 targeting antibody, and the Antibody Radiation Conjugate (ARC) comprised of apamistamab and the radioisotope iodine-131 used in the Company's lead Phase 3 candidate, Iomab-B, and its Iomab-ACT programs
Actinium Strengthens Leadership Team with Appointment of Dr. Avinash Desai as Executive Vice President of Clinical Development, Operations and Medical Affairs
- Dr. Desai has over twenty-five years of hematology and oncology-focused clinical development and medical affairs experience, including the successful launches of targeted therapies, monoclonal antibodies, and PARP inhibitors
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that it will be participating in the Alliance Global Partners' Virtual Healthcare Symposium being held on Thursday, November 19, 2020 . During the event, Actinium's Chief Medical Officer Mark Berger will participate in a panel discussing emerging tre
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that it will host a CD33 program update featuring two key opinion leaders (KOLs) today, November 11th at 4:15 PM ET
- Multi-dosing portion of Fusion's Phase 1 study of FPI-1434 on track to be initiated in Q4 2020 - Company executes collaboration agreement with AstraZeneca to grow pipeline of next-generation radiopharmaceuticals
EANM 2020: ITM Emphasizes Commitment to Developing Targeted Radionuclide Therapies With Satellite Symposium on Bone Metastases
ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical group of companies, invited to a virtual satellite symposium at the EANM Congress 2020 on reviewing “Challenges and Innovative Approaches in the Management of Osteoblastic Metastatic Disease”.
Actinium Announces Two Oral Presentations Featuring Data and Findings from the Phase 3 SIERRA Trial of Iomab-B at the 62nd American Society of Hematology Annual Meeting
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that two abstracts on the Company's Antibody Radiation Conjugate (ARC) Iomab-B were accepted for oral presentations at the 2020 American Society of Hematology (ASH) annual meeting that is being held virtually December 5-8, 2020.
100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 Combination Trial in Patients with Relapsed or Refractory AML
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that 100% of evaluable patients in the third and planned final dose cohort of the Actimab-A CLAG-M Phase 1 trial being conducted at the Medical College of Wisconsin (MCW) achieved remission.
Actinium Announces Actimab-A Venetoclax First-in-Human Data Accepted for Poster Presentation at the 62nd American Society of Hematology Annual Meeting
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that data from the Phase 1 portion of the Actimab-A venetoclax Phase 1/2 combination trial, has been accepted for poster presentation at the 2020 American Society of Hematology (ASH) annual meeting that is being held virtually December 5-8, 2020.
Fusion Pharmaceuticals Announces Collaboration with AstraZeneca to Develop and Commercialize Next-Generation Radiopharmaceuticals and Combination Therapies
Collaboration Combines Fusion's Targeted Alpha Therapies (TATs) Platform with AstraZeneca's Antibody and Oncology Portfolio to Create Novel Cancer Therapies
- Multiple milestones expected in the Fourth Quarter from the Company's ARC pipeline including Phase 3 data from the pivotal SIERRA trial for Iomab-B and Actimab-A combination trials with CLAG-M and venetoclax - Ad hoc interim analysis from SIERRA to be completed by year end
Promising New Cancer Treatments Advancing Through The Pipeline In Over $200 Billion Dollar Drug Market
Cancer immunotherapy has emerged as a new avenue for revenue generation for pharmaceutical companies.
Actinium Pharmaceuticals, Inc. Awarded Grant by National Institutes of Health to Study Novel Iomab-ACT Targeted Conditioning with a CD19 CAR T-Cell Therapy
NIH grant to support first of its kind clinical trial to use Antibody Radio-Conjugate for targeted conditioning prior to CAR T-cell therapy in patients with acute lymphoblastic leukemia and diffuse large B-cell lymphoma
10/15/2020Find out which life sciences companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.
RayzeBio Launches with $45 Million Series A to Advance Portfolio of Targeted Radiopharmaceuticals for Cancer Therapeutics
RayzeBio, Inc. announced today a $45M Series A financing to advance the development of its broad pipeline of targeted radiopharmaceuticals. Co-lead investors venBio Partners and Versant Ventures were joined by Sam
Actinium Pharmaceuticals, Inc. Expands R&D Capabilities with New Research Facility to Enhance Development of Next Generation Antibody Radiation Conjugates Leveraging Its Proprietary AWE Platform
Actinium Pharmaceuticals, Inc. announced the launch of its new research and development lab facility in New York City.
Actinium Pharmaceuticals, Inc. Announces Clinical Trial Site Expansion in its Multi-Center Phase 1/2 Actimab-A Venetoclax Combination Trial
Actinium Pharmaceuticals, Inc. announced that the University of Louisville and the Ochsner Clinic in New Orleans, Louisiana are now active trial sites in its Phase 1/2 Actimab-A venetoclax combination trial for patients with Relapsed or Refractory Acute Myeloid Leukemia age 18 and above.
Actinium Pharmaceuticals Successfully Completes First Dosing Cohort in the Phase 1 Study of Actimab-A and Venetoclax Combination Therapy in Relapsed/Refractory AML Patients
Combination trial, led by UCLA Medical Center and Principal Investigator Gary Shiller, MD, supported by mechanistic rationale and demonstrated synergy of combining venetoclax with targeted radiation from Actimab-A in preclinical studies
Actinium Pharmaceuticals Announces Successful Completion of Planned Phase 1 Actimab-A CLAG-M Combination Trial in Patients with Relapsed/Refractory AML at Medical College of Wisconsin
- Trial results including data from third dose cohort to be presented by year end; - Second dose cohort demonstrated 86% complete remission rate with 71% of patients achieving negative minimal residual disease status, as previously reported
Actinium Pharmaceuticals, Inc. to Present at the 22nd Annual H.C. Wainwright Global Investor Conference
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that its Chairman and Chief Executive Officer Sandesh Seth will be presenting at the virtual H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14 th at 2:00 PM EST .